Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

crossref(2023)

Cited 0|Views1
No score
Abstract
Table S4: Hits from the genome-wide shRNA screen in αEPHA2-Cond cells.
More
Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined